Tuberculosis Infection Clinical Trial
Official title:
Open Label, Single Center, Phase 1 Dose Escalation and Extension Trial to Evaluate Safety and Tolerability of Chlorquine as Adjuvant Drug to Standard 4-drug Anti-tuberculosis Therapy in Healthy Volunteers
In vitro and in vivo data show promising results of adjunctive use of Chloroquine to standard tuberculosis therapy as Chloroquine enhances animicrobial effectiveness against intracellular MTB. To date, no safety data of the concurrent use of both treatments is availble. In a phase I trial, the investigators aim to evaluate safety and tolerability of the concurrent use of Chloroquine and standard anti-TB drug in healthy volunteers.
Status | Recruiting |
Enrollment | 16 |
Est. completion date | December 1, 2024 |
Est. primary completion date | July 4, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion criteria: 1. Informed study-specific consent (including possible pharmacogenetic analysis) as documented by signature 2. Healthy volunteers aged between 18 and 50 years of age (significantly increased risk of side effects from 50 years of age with Rimstar®) Exclusion criteria: 1. Lack of highly effective contraception during the study treatment and for 8 months after the last dose of study treatment (until Day 254, visit 7) according to 11.4 with the following consideration for participating women: - From Day 1 (visit 2) up to Day 30 (visit 6) hormonal contraception is insufficient due to lower concentrations of estrogen and/or gestagen during and up to 14 days after Rimstar® intake. The hormonal contraception must be supplemented with a barrier method (preferably male condom). - From Day 30 (visit 6) up to Day 254 (visit 7) hormonal contraceptive methods can be used and are considered highly effective. 2. Pregnant or lactating females 3. Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product, glucose-6-phosphate dehydrogenase insufficiency (favism) 4. Regular treatment with drugs in the last 14 days prior to first intake of study drug (except for Paracetamol and Vitamin B6 (pyridoxine), see 8.7). 5. History of or concurrent, clinically significant cardiac, immunological, pulmonary, neurological, renal, gastrointestinal, dermatological, endocrinological or other major disease as determined by the Investigator and/or his representative 6. History of or presence of any clinically significant abnormality in vital signs, ECG, or laboratory test results or has any medical or psychiatric condition that, in the opinion of the Investigator, may interfere with the study procedures or compromise subject safety 7. History of or currently present retinopathy or other disturbances of the field of vision or the retina according to the Investigator 8. History of alcohol or substance abuse for the last 3 months prior to Screening, as determined by the Investigator 9. Weight less than 55kg 10. Intake of grapefruit juice or grapefruits within 2 weeks before the first study drug administration and during treatment phase 11. Donation of blood or blood products within a 30-day period prior to Screening 12. Current enrolment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months of participation to the Clear trial. 13. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant 14. The investigator, his/her family members, employees and other dependent persons |
Country | Name | City | State |
---|---|---|---|
Switzerland | Clinical Trial Center | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physicial examination 1.1 | Heart auscultation (normal/abnormal) | day 14 | |
Primary | Physicial examination 1.2 | Heart auscultation (normal/abnormal) | day 30 | |
Primary | Physicial examination 2.1 | lung auscultation (normal, abnormal) | day 14 | |
Primary | Physicial examination 2.2 | lung auscultation (normal, abnormal) | day 30 | |
Primary | Physicial examination 3.1 | abdominal examination (normal, abnormal) | day 14 | |
Primary | Physicial examination 3.2 | abdominal examination (normal, abnormal) | day 30 | |
Primary | Physicial examination 4.1 | lymph node palpation (normal, abnormal) | day 14 | |
Primary | Physicial examination 4.2 | lymph node palpation (normal, abnormal) | day 30 | |
Primary | Physicial examination 5.1 | reflex testing (normal, abnormal) | day 14 | |
Primary | Physicial examination 5.2 | reflex testing (normal, abnormal) | day 30 | |
Primary | Physicial examination 6.1 | test vibration sense with tuning fork (mallelor left and right X/8) | day 14 | |
Primary | Physicial examination 6.2 | test vibration sense with tuning fork (mallelor left and right X/8) | day 30 | |
Primary | Vital Signs 1.1 | heart rate (beats/min) | day 1 | |
Primary | Vital Signs 1.2 | heart rate (beats/min) | day 7 | |
Primary | Vital Signs 1.3 | heart rate (beats/min) | day 14 | |
Primary | Vital Signs 1.4 | heart rate (beats/min) | day 15 | |
Primary | Vital Signs 1.5 | heart rate (beats/min) | day 30 | |
Primary | Vital Signs 2.1 | blood pressure (mmHg) | day 1 | |
Primary | Vital Signs 2.2 | blood pressure (mmHg) | day 7 | |
Primary | Vital Signs 2.3 | blood pressure (mmHg) | day 14 | |
Primary | Vital Signs 2.4 | blood pressure (mmHg) | day 15 | |
Primary | Vital Signs 2.5 | blood pressure (mmHg) | day 30 | |
Primary | Vital Signs 3.1 | temperature (°C) | day 1 | |
Primary | Vital Signs 3.2 | temperature (°C) | day 7 | |
Primary | Vital Signs 3.3 | temperature (°C) | day 14 | |
Primary | Vital Signs 3.4 | temperature (°C) | day 15 | |
Primary | Vital Signs 3.5 | temperature (°C) | day 30 | |
Primary | Safety Laboratory samples Panel 1.1 | Sodium (mmol/l) | day 1 | |
Primary | Safety Laboratory samples Panel 1.2 | Sodium (mmol/l) | day 7 | |
Primary | Safety Laboratory samples Panel 1.3 | Sodium (mmol/l) | day 14 | |
Primary | Safety Laboratory samples Panel 1.4 | Sodium (mmol/l) | day 30 | |
Primary | Safety Laboratory samples Panel 2.1 | Potassium (mmol/l) | day 1 | |
Primary | Safety Laboratory samples Panel 2.2 | Potassium (mmol/l) | day 7 | |
Primary | Safety Laboratory samples Panel 2.3 | Potassium (mmol/l) | day 14 | |
Primary | Safety Laboratory samples Panel 2.4 | Potassium (mmol/l) | day 30 | |
Primary | Safety Laboratory samples Panel 3.1 | Calcium (mmol/l) | day 1 | |
Primary | Safety Laboratory samples Panel 3.2 | Calcium (mmol/l) | day 7 | |
Primary | Safety Laboratory samples Panel 3.3 | Calcium (mmol/l) | day 14 | |
Primary | Safety Laboratory samples Panel 3.4 | Calcium (mmol/l) | day 30 | |
Primary | Safety Laboratory samples Panel 4.1 | Creatinine (umol/l) | day 1 | |
Primary | Safety Laboratory samples Panel 4.2 | Creatinine (umol/l) | day 7 | |
Primary | Safety Laboratory samples Panel 4.3 | Creatinine (umol/l) | day 14 | |
Primary | Safety Laboratory samples Panel 4.4 | Creatinine (umol/l) | day 30 | |
Primary | Safety Laboratory samples Panel 5.1 | Total Bilirubin (umol/l) | day 1 | |
Primary | Safety Laboratory samples Panel 5.2 | Total Bilirubin (umol/l) | day 7 | |
Primary | Safety Laboratory samples Panel 5.3 | Total Bilirubin (umol/l) | day 14 | |
Primary | Safety Laboratory samples Panel 5.4 | Total Bilirubin (umol/l) | day 30 | |
Primary | Safety Laboratory samples Panel 6.1 | ALT (U/l) | day 1 | |
Primary | Safety Laboratory samples Panel 6.2 | ALT (U/l) | day 7 | |
Primary | Safety Laboratory samples Panel 6.3 | ALT (U/l) | day 14 | |
Primary | Safety Laboratory samples Panel 6.4 | ALT (U/l) | day 30 | |
Primary | Safety Laboratory samples Panel 7.1 | Glucose (mmol/l) | day 1 | |
Primary | Safety Laboratory samples Panel 7.2 | Glucose (mmol/l) | day 7 | |
Primary | Safety Laboratory samples Panel 7.3 | Glucose (mmol/l) | day 14 | |
Primary | Safety Laboratory samples Panel 7.4 | Glucose (mmol/l) | day 30 | |
Primary | Safety Laboratory samples Panel 8.1 | CRP (mg/l) | day 1 | |
Primary | Safety Laboratory samples Panel 8.2 | CRP (mg/l) | day 7 | |
Primary | Safety Laboratory samples Panel 8.3 | CRP (mg/l) | day 14 | |
Primary | Safety Laboratory samples Panel 8.4 | CRP (mg/l) | day 30 | |
Primary | Safety Laboratory samples Panel 9.1 | Haemoglobin (g/l) | day 1 | |
Primary | Safety Laboratory samples Panel 9.2 | Haemoglobin (g/l) | day 7 | |
Primary | Safety Laboratory samples Panel 9.3 | Haemoglobin (g/l) | day 14 | |
Primary | Safety Laboratory samples Panel 9.4 | Haemoglobin (g/l) | day 30 | |
Primary | Safety Laboratory samples Panel 10.1 | Platlets (G/l) | day 1 | |
Primary | Safety Laboratory samples Panel 10.2 | Platlets (G/l) | day 7 | |
Primary | Safety Laboratory samples Panel 10.3 | Platlets (G/l) | day 14 | |
Primary | Safety Laboratory samples Panel 10.4 | Platlets (G/l) | day 30 | |
Primary | Safety Laboratory samples Panel 11.1 | White blood cell (G/l) | day 1 | |
Primary | Safety Laboratory samples Panel 11.2 | White blood cell (G/l) | day 7 | |
Primary | Safety Laboratory samples Panel 11.3 | White blood cell (G/l) | day 14 | |
Primary | Safety Laboratory samples Panel 11.4 | White blood cell (G/l) | day 30 | |
Primary | Safety Laboratory samples Panel 12.1 | Blood pregnancy test (Blood beta-hCG) | day 7 | |
Primary | Safety Laboratory samples Panel 12.2 | Blood pregnancy test (Blood beta-hCG) | day 30 | |
Primary | Urinanalysis 1.1 | Dipstick: protein negative/+/++/+++ | day 1 | |
Primary | Urinanalysis 1.2 | Dipstick: protein negative/+/++/+++ | day 7 | |
Primary | Urinanalysis 1.3 | Dipstick: protein negative/+/++/+++ | day 14 | |
Primary | Urinanalysis 1.4 | Dipstick: protein negative/+/++/+++ | day 30 | |
Primary | Urinanalysis 2.1 | Dipstick: white blood cells negative/+/++/+++ | day 1 | |
Primary | Urinanalysis 2.2 | Dipstick: white blood cells negative/+/++/+++ | day 7 | |
Primary | Urinanalysis 2.3 | Dipstick: white blood cells negative/+/++/+++ | day 14 | |
Primary | Urinanalysis 2.4 | Dipstick: white blood cells negative/+/++/+++ | day 30 | |
Primary | Urinanalysis 3.1 | Dipstick: red blood cells negative/+/++/+++ | day 1 | |
Primary | Urinanalysis 3.2 | Dipstick: red blood cells negative/+/++/+++ | day 7 | |
Primary | Urinanalysis 3.3 | Dipstick: red blood cells negative/+/++/+++ | day 14 | |
Primary | Urinanalysis 3.4 | Dipstick: red blood cells negative/+/++/+++ | day 30 | |
Primary | Urinanalysis 4.1 | Dipstick: Glucose negative/+/++/+++ | day 1 | |
Primary | Urinanalysis 4.2 | Dipstick: Glucose negative/+/++/+++ | day 7 | |
Primary | Urinanalysis 4.3 | Dipstick: Glucose negative/+/++/+++ | day 14 | |
Primary | Urinanalysis 4.4 | Dipstick: Glucose negative/+/++/+++ | day 30 | |
Primary | Safety 12 lead ECG 1.1 | Rate/min | day 7 | |
Primary | Safety 12 lead ECG 1.2 | Rate/min | 30 | |
Primary | Safety 12 lead ECG 2.1 | Rhythm (regular/irregular) | day 7 | |
Primary | Safety 12 lead ECG 2.2 | Rhythm (regular/irregular) | day 30 | |
Primary | Safety 12 lead ECG 3.1 | PQ interval (ms) | day 7 | |
Primary | Safety 12 lead ECG 3.3 | PQ interval (ms) | day 30 | |
Primary | Safety 12 lead ECG 4.1 | QRS interval (ms) | day 7 | |
Primary | Safety 12 lead ECG 4.2 | QRS interval (ms) | day 30 | |
Primary | Safety 12 lead ECG 5.1 | ST Segment (normal/elevation/depression) | day 7 | |
Primary | Safety 12 lead ECG 5.2 | ST Segment (normal/elevation/depression) | day 30 | |
Primary | Safety ophtalmological examination 1.1 | Slit lamp examaniation both sides (normal/abnormal) | day 30 | |
Primary | Safety ophtalmological examination 1.2 | Refraction both sides (+/-) | day 30 | |
Primary | Safety ophtalmological examination 1.3 | Biomicroscopy of the central fundus both sides(normal/abnormal) | day 30 | |
Primary | Safety ophtalmological examination 1.4 | Applanation tonometry and stereoscopic papilla evaluation bilateral (normal/abnormal), Color sense test according to Panel D-15 right and left side (normal/abnormal) | day 30 | |
Primary | Safety ophtalmological examination 1.5 | Color sense test according to Panel D-15 bilateral (normal/abnormal) | day 30 | |
Primary | Occurence of adverse events and serious adverse events 1.1 | according to GCP Guideline | day 1 | |
Primary | Occurence of adverse events and serious adverse events 1.2 | according to GCP Guideline | day 7 | |
Primary | Occurence of adverse events and serious adverse events 1.3 | according to GCP Guideline | day 14 | |
Primary | Occurence of adverse events and serious adverse events 1.4 | according to GCP Guideline | day 15 | |
Primary | Occurence of adverse events and serious adverse events 1.5 | according to GCP Guideline | day 30 | |
Primary | Occurence of adverse events and serious adverse events 1.6 | according to GCP Guideline | day 256 | |
Secondary | Drug concentration over time measured by the pharmacokinetics | drug concentration (mg/l) of Rifampicin, Isoniazid, 25-O-Desacetylrifampicin, Ethambutol, Pyrazinamide, Chloroquine, Desethylchloroquine | day 14 prior to dosing (-15 until -5 minutes) and 1, 2, 4, 6 and 24 hours after dosing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Completed |
NCT04545164 -
Computer Aided Screening for Tuberculosis in Low Resource Environments
|
N/A | |
Recruiting |
NCT05766267 -
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05756582 -
Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
|
||
Enrolling by invitation |
NCT04988984 -
Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)
|
||
Recruiting |
NCT04148053 -
Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
|
||
Recruiting |
NCT01689831 -
Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)
|
Phase 2 | |
Completed |
NCT05945498 -
Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years
|
Phase 1 | |
Not yet recruiting |
NCT06352970 -
Effects of Tuberculosis Infection on Development and Function of the Placenta
|
||
Recruiting |
NCT04575519 -
Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
|
Phase 2 | |
Recruiting |
NCT05413551 -
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
|
Phase 1 | |
Recruiting |
NCT03941210 -
Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
|
||
Completed |
NCT04494516 -
Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
|
||
Withdrawn |
NCT03265977 -
A Phase II Study of H56:IC31 in Healthy Adolescents
|
Phase 2 | |
Recruiting |
NCT05069688 -
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
|
Phase 1 | |
Suspended |
NCT05330884 -
BCG Revaccination in Children and Adolescents
|
Phase 3 | |
Recruiting |
NCT05342064 -
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
|
N/A | |
Recruiting |
NCT05236452 -
Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection
|
N/A | |
Recruiting |
NCT05122026 -
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
|
Phase 1/Phase 2 | |
Recruiting |
NCT06221488 -
Testing Health Workers At Risk to Advance Our Understanding of TB Infection
|